NEW ORLEANS, June 07, 2026 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing portal-hepatic targeted therapies for metabolic disease, announced ...

Research led by scientists from the Universities of Oxford and Edinburgh has found that early good blood glucose control can minimize the lifetime risk of diabetes-related complications, including ...

In a recent study published in Nature, researchers report the design and experimental efficacies of NNC2215, a novel insulin conjugate comprising synthetically added glucose-binding macrocycles and ...

It is important to identify people with type 2 diabetes at the earliest opportunity, target good glucose control immediately after diagnosis, and maintain it as long as possible, to reduce the risks ...

Neurons in the ventromedial nucleus of the hypothalamus that express the cholecystokinin b receptor (VMH Cckbr neurons) appear to support glucose production during hypoglycemia without broadly ...

For patients recovering after cardiac surgery, a new algorithm based on artificial intelligence (AI) could streamline the process of tracking shifts in glucose and adjusting insulin accordingly, ...

Millions of Americans struggle with unpredictable blood sugar swings that leave them feeling exhausted, moody, and constantly battling cravings. The rollercoaster of glucose highs and lows doesn’t ...

HDV-Insulin Lispro (HDV-LIS) met A1C non-inferiority at Weeks 12 and 25, confirming comparable glycemic control to insulin lispro (LIS) with point-estimate differences below FDA-required 0.1% ...

Three-dimensional rendering of a hepatocyte-directed vesicle (HDV), the delivery platform underlying HDV-insulin lispro. The disc-shaped phospholipid bilayer carries biotin (green) as a ...

(MENAFN- GlobeNewsWire - Nasdaq) The OPTI-2 trial provides early clinical evidence that liver-targeted mealtime insulin may help decouple tight glucose control from hypoglycemia risk, a longstanding ...